EyePoint Pharmaceuticals (NASDAQ:EYPT) reported quarterly losses of $(0.81) per share which missed the analyst consensus estimate of $(0.73) by 11.11 percent. This is a 26.56 percent decrease over losses of $(0.64) per share from the same period last year. The company reported quarterly sales of $620.000 thousand which missed the analyst consensus estimate of $1.010 million by 38.61 percent. This is a 94.65 percent decrease over sales of $11.588 million the same period last year.